GZMK and type 2 diabetes mellitus: Recently, Tirzepatide, a dual GIP/GLP-1 receptor agonist demonstrated superior glucose and body-weight lowering properties to GLP-1 receptor agonism (GLP-1RA) in T2D subjects and (28) so it will be important to assess whether GIP-R is involved in the effect of GRK inhibition.